Option & Evaluation Partnership Terms & Agreements in Global Pharma, Biotech and Diagnostics (2014-2019) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Option and Evaluation Partnership Terms and Agreements in Pharma,
Biotech and Diagnostics 2014-2019” report has been added to ResearchAndMarkets.com’s
offering.

This report provides details of the latest option and evaluation
agreements announced in the pharmaceutical, biotechnology and diagnostic
sectors. Fully revised and updated, the report provides details of
option and evaluation agreements from 2014 to 2019.

There are two major forms of deal term that allow a party to a deal to
secure rights to an asset subject to a future event; namely, option and
evaluation.

Evaluation agreements allow a party to the deal to obtain rights to a
technology or compound, subject to a period of time to evaluate the
quality, scope and applicability of the technology to its intended
endpoint. Normally the technology is at an early stage and/or unproven
and the partnering company wishes to assess the technology as part of
the due diligence process in advance of signing a long term licensing
agreement.

Evaluation agreements have been a mainstay of technology licensing from
the earliest days.

An option agreement differs in that the option is often an integral part
of an agreement already entered by the parties, providing the party with
the option right to retain or extend certain rights to the technology
already partnered.

Option agreements are becoming increasingly popular as they create
additional flexibility within a deal for additional rights that the
parties do not wish to commit at the outset of the agreement.

This report focuses on option and evaluation agreements and clauses
within broader agreements between big pharma-big pharma, big pharma –
smaller company, and smaller company-smaller company, providing a
detailed insight into all such deals.

The report provides a detailed understanding and analysis of how and why
companies enter option and evaluation deals. The majority of deals are
multicomponent whereby the licensor retains either a option and
evaluation right to the resultant product of the research collaboration.
There are also numerous pure option and evaluation deals whereby the
products originator takes on a partner in order to advance the product
or compound to a point where the licensee might seek to proceed to a
licensing deal.

Understanding the flexibility of a prospective partner’s negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases
and databases do not.

This report contains a comprehensive listing of all option and
evaluation deals announced since 2014 as recorded in the deals and
alliances database, including financial terms where available, plus
links to online copies of actual option and evaluation contract
documents as submitted to the Securities Exchange Commission by
companies and their partners.

Contract documents provide the answers to numerous questions about a
prospective partner’s flexibility on a wide range of important issues,
many of which will have a significant impact on each party’s ability to
derive value from the deal.

The initial chapters of this report provide an orientation of option and
evaluation dealmaking and business activities. Chapter 1 provides an
introduction to the report, whilst chapter 2 provides an analysis of the
trends in option and evaluation as well as a discussion on the merits of
the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation
deals. The chapter includes numerous case studies to enable
understanding of both pure option and evaluation deals and
multicomponent deals where option and evaluation forms a part.

Chapter 4 provides a review of the leading option and evaluation deals
since 2014. Deals are listed by headline value, signed by big pharma and
big biotech and most active of all biopharma companies. When the deal
has an agreement contract published at the SEC, a link provides online
access to the contract via the deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 most active
option and evaluation dealmaker companies. Each deal title links via
Current Agreements deals and alliances database to an online version of
the full deal record, and where available, the actual contract document,
providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of option and
evaluation deals signed and announced since 2014 where a contract
document is available. Contract documents provide an in-depth insight
into the actual deal terms agreed between the parties with respect to
the option and evaluation deal.

In addition the report includes a series of appendices containing a
comprehensive listing of all option and evaluation deals announced since
2014.

Each listing is organized as an appendix by company A-Z, stage of
development at signing, and therapeutic area. Each deal title links via
hyperlink to an online version of the deal record including, where
available, the actual contract document.

The report includes deals announced by hundreds of life science
companies including big pharma such as Abbott, Abbvie, Actavis, Amgen,
Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai,
Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan,
Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant,
amongst many others.

The report also includes numerous tables and figures that illustrate the
trends and activities in option and evaluation dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker
needs to know about option and evaluation alliances.

Key Benefits

• In-depth understanding of option and evaluation deal trends since 2014
• Analysis of the structure of option and evaluation agreements with
  numerous real life case studies
• Comprehensive access to over 1,000 actual option and evaluation deals
  entered into by the world’s biopharma companies
• Detailed access to actual option and evaluation contracts enter into
  by the leading fifty big pharma companies
• Insight into the terms included in a option and evaluation agreement,
  together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal
  terms for partner companies

Report Scope

This report is intended to provide the reader with an in-depth
understanding of the option and evaluation trends and structure of deals
entered into by leading biopharma companies worldwide.

The report includes:

• Trends in option and evaluation dealmaking in the biopharma industry
  since 2014
• Analysis of option and evaluation deal structure
• Case studies of real-life option and evaluation deals
• Access to over 1,000 option and evaluation deal records
• The leading option and evaluation deals by value since 2014
• Most active option and evaluation dealmakers since 2014
• The leading option and evaluation partnering resources

In the report, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Therapeutic area
• Technology type

Each deal title links via Weblink to an online version of the actual
deal record, providing easy access to each contract document where
available.

The report provides comprehensive access to available records for over
1,000 option and evaluation deals, including contract documents where
available.

Analyzing actual contract agreements allows assessment of the
following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sub-licensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or
  deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

For more information about this report visit https://www.researchandmarkets.com/research/c2s85d/option_and?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology,
Pharmaceuticals,
Diagnostics